Proposed Data Collection Submitted for Public Comment and Recommendations, 46119-46120 [2024-11591]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 103 / Tuesday, May 28, 2024 / Notices
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2024–11589 Filed 5–24–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day-24–24FS; Docket No. CDC–2024–
0038]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed information collection, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comments on a proposed information
collection titled Needle Exchange
Utilization Survey (NEXUS). This data
collection is being created to develop a
surveillance system to monitor drug use,
prevention behaviors, and the infectious
disease consequences of drug use in
select urban and non-urban areas of the
U.S.
DATES: CDC must receive written
comments on or before July 29, 2024.
ADDRESSES: You may submit comments
identified by Docket No. CDC–2024–
0038 by either of the following methods:
• Federal eRulemaking Portal:
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
www.regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(www.regulations.gov) or by U.S. mail to
the address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:43 May 24, 2024
Jkt 262001
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
H21–8, Atlanta, Georgia 30329;
Telephone: 404–639–7118; Email: omb@
cdc.gov.
SUPPLEMENTARY INFORMATION:
Under the Paperwork Reduction Act
of 1995 (PRA) (44 U.S.C. 3501–3520),
Federal agencies must obtain approval
from the Office of Management and
Budget (OMB) for each collection of
information they conduct or sponsor. In
addition, the PRA also requires Federal
agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each new proposed
collection, each proposed extension of
the existing collection of information,
and each reinstatement of previously
approved information collection before
submitting the collection to the OMB for
approval. To comply with this
requirement, we are publishing this
notice of a proposed data collection as
described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of collecting
information on those to respond,
including using appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic responses;
and
5. Assess information collection costs.
Proposed Project
Needle Exchange Utilization Survey
(NEXUS)—New—National Center for
HIV, Viral Hepatitis, STD, and TB
Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
The purpose of the Needle Exchange
Utilization Survey (NEXUS) is to
develop a surveillance system to
monitor drug use, prevention behaviors,
and the infectious disease consequences
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
46119
of drug use in 6–15 select urban and
non-urban areas of the U.S. that the
opioid crisis has impacted. Such a
surveillance system is needed to inform
prevention efforts and policy. The
specific objectives of the project are to
assess the following among persons who
inject drugs who are recruited in syringe
services programs (SSPs) and their peers
who use drugs through peer-driven
recruitment: (1) drug use and sexual
behaviors, injection risk networks,
receipt of prevention services, and
barriers to prevention and care; and (2)
the prevalence of HIV and hepatitis C
(HCV) infections.
The project will involve a two-stage
sampling approach. First, up to 15 SSPs
will be selected to ensure geographic
diversity and representation of key
program characteristics, such as the
syringe distribution model (needs-based
vs. all others) and length in operation
(<5 years, ≥5 years). Second, SSP
clients, the majority who are persons
who inject drugs (PWID), and their
peers who use drugs will be recruited
through a combination of direct
recruitment at each SSP and peer-driven
recruitment to partake in a survey and
HCV and HIV testing.
Clients of SSPs and their peers who
meet eligibility criteria will complete a
survey using an Electronic Data Capture
system, a secure web-based application
for administering online surveys. The
survey will include questions on drug
use and sexual behaviors, injection risk
networks, drug treatment history,
history of drug use-related adverse
health outcomes, experiences with law
enforcement, HIV and HCV testing
experience, and use of prevention and
health care services. Lastly, participants
will be offered anonymous HIV and
HCV testing in conjunction with the
survey, which they may refuse with no
effect on participation in the survey.
Data from NEXUS will be used to
inform the planning and evaluation of
prevention programs at the local and
national levels that aim to reduce
adverse health outcomes due to
injection and non-injection drug use
and to contribute to the overall opioid
crisis response efforts. Data from
NEXUS will also be used for an ongoing
surveillance system in the U.S. to
monitor trends in drug use and the
infectious disease consequences of drug
use.
Approximately 6,000 individuals will
complete the eligibility screener. Our
target population is 300 participants per
site or 4,500 for up to 15 sites. We
anticipate that, on average, 25% or
1,499 persons (for up to 15 SSPs) will
not be interested in completing a
questionnaire, yielding a maximum of
E:\FR\FM\28MYN1.SGM
28MYN1
46120
Federal Register / Vol. 89, No. 103 / Tuesday, May 28, 2024 / Notices
6,000 eligible participants. The total
annualized burden is 3,126 hours. There
are no other costs to respondents other
than their time.
ESTIMATED ANNUALIZED BURDEN HOURS
No. of
responses
per
respondent
Average
burden per
response
(hours)
Total
burden
(in hours)
Form
Persons Screened ....................................
Persons Screened ....................................
Persons who give permission ...................
Persons who give permission ...................
Eligible Participants ...................................
Eligible Participants ...................................
Eligibility Screening Form English ............
Eligibility Screening Form Spanish ..........
Model Project Consent Form English ......
Model Project Permission Form Spanish
NEXUS Survey English ............................
NEXUS Survey Spanish ...........................
5,400
600
4,050
450
4,050
450
1
1
1
1
1
1
5/60
5/60
5/60
5/60
30/60
30/60
450
50
338
38
2,025
225
Total ...................................................
...................................................................
....................
....................
....................
3,126
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2024–11591 Filed 5–24–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–24–24FU; Docket No. CDC–2024–
0039]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed information collection, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on a proposed information
collection project titled Assessing
Capacity to Expand Hepatitis C Testing
and Treatment in United States Carceral
Systems. This data collection proposes
to estimate point prevalence of hepatitis
C virus in carceral settings, outline
patient characteristics, clinical
management, and understand key
operational and programmatic successes
and challenges to testing and treatment
of hepatitis C virus, as well as to
support timely analysis and utilize
findings to advance the elimination of
viral hepatitis in the United States.
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
No. of
respondents
Respondent
VerDate Sep<11>2014
19:14 May 24, 2024
Jkt 262001
CDC must receive written
comments on or before July 29, 2024.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2024–
0039 by either of the following methods:
• Federal eRulemaking Portal:
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
www.regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(www.regulations.gov) or by U.S. mail to
the address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road, NE, MS
H21–8, Atlanta, Georgia 30329;
Telephone: 404–639–7570; Email: omb@
cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
DATES:
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
5. Assess information collection costs.
Proposed Project
Assessing Capacity to Expand
Hepatitis C Testing and Treatment in
United States Carceral Systems—New—
National Center for HIV, Viral Hepatitis,
STD, and TB Prevention (NCHHSTP),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
Carceral settings pose a unique
challenge to hepatitis C elimination in
that data, as it relates to hepatitis C
virus testing and treatment, is not
readily available for analysis to
understand the burden of disease within
this environment. To our knowledge,
CDC does not have a repository of data
specifically directed towards hepatitis C
within State Department of Corrections
(DOC) or large jails. This survey
E:\FR\FM\28MYN1.SGM
28MYN1
]]>Agencies
[Federal Register Volume 89, Number 103 (Tuesday, May 28, 2024)]
[Notices]
[Pages 46119-46120]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-11591]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-24-24FS; Docket No. CDC-2024-0038]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing effort to reduce public burden and maximize the
utility of government information, invites the general public and other
Federal agencies the opportunity to comment on a proposed information
collection, as required by the Paperwork Reduction Act of 1995. This
notice invites comments on a proposed information collection titled
Needle Exchange Utilization Survey (NEXUS). This data collection is
being created to develop a surveillance system to monitor drug use,
prevention behaviors, and the infectious disease consequences of drug
use in select urban and non-urban areas of the U.S.
DATES: CDC must receive written comments on or before July 29, 2024.
ADDRESSES: You may submit comments identified by Docket No. CDC-2024-
0038 by either of the following methods:
Federal eRulemaking Portal: www.regulations.gov. Follow
the instructions for submitting comments.
Mail: Jeffrey M. Zirger, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS H21-8, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. CDC will post, without change, all relevant comments
to www.regulations.gov.
Please note: Submit all comments through the Federal eRulemaking
portal (www.regulations.gov) or by U.S. mail to the address listed
above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact Jeffrey M. Zirger, Information Collection
Review Office, Centers for Disease Control and Prevention, 1600 Clifton
Road NE, MS H21-8, Atlanta, Georgia 30329; Telephone: 404-639-7118;
Email: [email protected].
SUPPLEMENTARY INFORMATION:
Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-
3520), Federal agencies must obtain approval from the Office of
Management and Budget (OMB) for each collection of information they
conduct or sponsor. In addition, the PRA also requires Federal agencies
to provide a 60-day notice in the Federal Register concerning each
proposed collection of information, including each new proposed
collection, each proposed extension of the existing collection of
information, and each reinstatement of previously approved information
collection before submitting the collection to the OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to
be collected;
4. Minimize the burden of collecting information on those to
respond, including using appropriate automated, electronic, mechanical,
or other technological collection techniques or other forms of
information technology, e.g., permitting electronic responses; and
5. Assess information collection costs.
Proposed Project
Needle Exchange Utilization Survey (NEXUS)--New--National Center
for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
The purpose of the Needle Exchange Utilization Survey (NEXUS) is to
develop a surveillance system to monitor drug use, prevention
behaviors, and the infectious disease consequences of drug use in 6-15
select urban and non-urban areas of the U.S. that the opioid crisis has
impacted. Such a surveillance system is needed to inform prevention
efforts and policy. The specific objectives of the project are to
assess the following among persons who inject drugs who are recruited
in syringe services programs (SSPs) and their peers who use drugs
through peer-driven recruitment: (1) drug use and sexual behaviors,
injection risk networks, receipt of prevention services, and barriers
to prevention and care; and (2) the prevalence of HIV and hepatitis C
(HCV) infections.
The project will involve a two-stage sampling approach. First, up
to 15 SSPs will be selected to ensure geographic diversity and
representation of key program characteristics, such as the syringe
distribution model (needs-based vs. all others) and length in operation
(<5 years, >=5 years). Second, SSP clients, the majority who are
persons who inject drugs (PWID), and their peers who use drugs will be
recruited through a combination of direct recruitment at each SSP and
peer-driven recruitment to partake in a survey and HCV and HIV testing.
Clients of SSPs and their peers who meet eligibility criteria will
complete a survey using an Electronic Data Capture system, a secure
web-based application for administering online surveys. The survey will
include questions on drug use and sexual behaviors, injection risk
networks, drug treatment history, history of drug use-related adverse
health outcomes, experiences with law enforcement, HIV and HCV testing
experience, and use of prevention and health care services. Lastly,
participants will be offered anonymous HIV and HCV testing in
conjunction with the survey, which they may refuse with no effect on
participation in the survey.
Data from NEXUS will be used to inform the planning and evaluation
of prevention programs at the local and national levels that aim to
reduce adverse health outcomes due to injection and non-injection drug
use and to contribute to the overall opioid crisis response efforts.
Data from NEXUS will also be used for an ongoing surveillance system in
the U.S. to monitor trends in drug use and the infectious disease
consequences of drug use.
Approximately 6,000 individuals will complete the eligibility
screener. Our target population is 300 participants per site or 4,500
for up to 15 sites. We anticipate that, on average, 25% or 1,499
persons (for up to 15 SSPs) will not be interested in completing a
questionnaire, yielding a maximum of
[[Page 46120]]
6,000 eligible participants. The total annualized burden is 3,126
hours. There are no other costs to respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
No. of Average
No. of responses burden per Total
Respondent Form respondents per response burden (in
respondent (hours) hours)
----------------------------------------------------------------------------------------------------------------
Persons Screened.................... Eligibility Screening 5,400 1 5/60 450
Form English.
Persons Screened.................... Eligibility Screening 600 1 5/60 50
Form Spanish.
Persons who give permission......... Model Project Consent 4,050 1 5/60 338
Form English.
Persons who give permission......... Model Project 450 1 5/60 38
Permission Form
Spanish.
Eligible Participants............... NEXUS Survey English.. 4,050 1 30/60 2,025
Eligible Participants............... NEXUS Survey Spanish.. 450 1 30/60 225
---------------------------------------------------
Total........................... ...................... ........... ........... ........... 3,126
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2024-11591 Filed 5-24-24; 8:45 am]
BILLING CODE 4163-18-P
